Key result
GSK-3 inhibition shows potential to stimulate endogenous cardiomyocyte proliferation and cardiac regeneration for HF repair.
Why the study?
Does inhibition of GSK-3 induce cardiomyocyte proliferation and cardiac regeneration?
Does inhibition of GSK-3 induce cardiomyocyte proliferation and cardiac regeneration?
GSK-3 inhibition emerges as a promising preclinical strategy to induce endogenous cardiomyocyte proliferation and cardiac regeneration for the treatment of heart failure.
Answers are grounded in this paper and cite their sources.
May support preclinical testing of GSK-3 inhibitors for cardiac repair; leaves open clinical translation in heart failure.
With an estimated 38 million current patients, heart failure (HF) is a leading cause of morbidity and mortality worldwide. Although the aetiology differs, HF is largely a disease of cardiomyocyte (CM) death or dysfunction. Due to the famously limited amount of regenerative capacity of the myocardium, the only viable option for advanced HF patients is cardiac transplantation; however, donor's hearts are in very short supply. Thus, novel regenerative strategies are urgently needed to reconstitute the injured hearts. Emerging data from our lab and others have elucidated that CM-specific deletion of glycogen synthase kinase (GSK)-3 family of kinases induces CM proliferation, and the degree of proliferation is amplified in the setting of cardiac stress. If this proliferation is sufficiently robust, one could induce meaningful regeneration without the need for delivering exogenous cells to the injured myocardium (i.e. cardiac regeneration in situ). Herein, we will discuss the emerging role of the GSK-3s in CM proliferation and differentiation, including their potential implications in cardiac regeneration. The underlying molecular interactions and cross-talk among signalling pathways will be discussed. We will also review the specificity and limitations of the available small molecule inhibitors targeting GSK-3 and their potential applications to stimulate the endogenous cardiac regenerative responses to repair the injured heart.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2018) conducted a review in Heart failure. GSK-3 inhibitors was evaluated. Inhibition of GSK-3 represents a potential therapeutic strategy to stimulate endogenous cardiomyocyte proliferation and induce in situ cardiac regeneration for heart failure repair.
Synapse has enriched 10 related papers. Consider them for comparative context: